DRI Healthcare focuses on acquiring and managing pharmaceutical royalty streams, particularly those addressing unmet medical needs in various therapeutic areas.

DRI Healthcare

DRI Healthcare | 3,469 followers on LinkedIn. Advancing science in the fast-growing pharmaceutical and biotechnology sector | DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors.

Investing in Biotechnology & Pharmaceuticals

Navin Jacob

Chief Financial Officer | Senior Finance Executive | Trusted Business Partner

Chris Anastasopoulos

Associate General Counsel at DRI Healthcare

Alyssa Klapper

Legal Counsel at DRI Healthcare

Yang (Serena) Li

Yesterday, we announced the acquisition of a synthetic royalty interest in the worldwide sales of sebestralstat for the treatment of hereditary angioedema (“HAE”) plus a private placement in KalVista Pharmaceuticals, Inc. for a total investment of up to US$184 million. If approved, sebetralstat would be the first and only oral on-demand therapy for treating attacks associated with HAE. This is the Trust’s first pre-approval royalty acquisition and first equity investment, highlight our evolving investment strategy. Read more: https://lnkd.in/gpWY7gg9

DRI Healthcare is looking for a Legal Associate to join our team! We are looking for a self-motivated and proactive attorney with corporate and transactional experience. If you or anyone you know is interested in applying, please feel free to reach out or click the link below. https://lnkd.in/gnQhey6Y

Today, we announced the acquisition of a portion of Editas Medicine, Inc.’s payment rights under a non-exclusive license to Vertex Pharmaceuticals Inc. of Editas Medicine’s Cas9 gene-editing technology for CASGEVY® (exagamglogene autotemcel) for an upfront purchase price of US$57 million. This transaction adds another innovative rare disease therapy to our portfolio, and the novel deal structure offers predictable annual cash flows as well as potential additional annual sales-based milestones and a one-time contingent payment. Read more: https://lnkd.in/g-DmcfSk

DRI is looking for a highly motivated and results-driven individual to join our Finance team as a Vice President, Finance. The Vice President, Finance will primarily be responsible for the corporate accounting, reporting, controls and systems related to DRI Capital Inc. If you or anyone you know is interested in applying, please feel free to reach out or click the link below. https://lnkd.in/gnQhey6Y

Today, we announced that DRI Healthcare has agreed to acquire an additional royalty interest in the worldwide sales of Xenpozyme (olipudase alfa) from HLS Therapeutics Inc. for up to US$45.75 million. Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency, also known as Niemann-Pick disease, in pediatric and adult patients. We made our first investment in Xenpozyme in November 2022. Xenpozyme has seen strong sales since it was approved in 2022 and we are excited to increase our exposure to this important treatment. Read more: https://lnkd.in/gJt-J62r

DRI Healthcare would like to welcome Ranee Borgna to the team as Executive Assistant & Office Coordinator.

DRI Healthcare would like to welcome David Jimenez to the team as Analyst, Asset Operations & Analytics.

DRI Healthcare would like to welcome Yang (Serena) Li to the team as Legal Counsel.

We are looking forward to presenting and continuing to advance the Canadian life sciences sector.

DRI is looking for a highly motivated and results driven individual to join our active and growing Investments & Research team as a Senior Analyst. If you or anyone you know is interested in applying, please feel free to reach out or click the link below. https://lnkd.in/gnQhey6Y

Metric
Company Name	DRI Healthcare
Symbol
MSH ID	COM:DRIHEALTHCARE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	CA
Stage
Employee Count
Website	drihealthcare.com
LinkedIn	dri-healthcare
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DRIH

COM:DRIHEALTHCARE

DRI Healthcare

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue